Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.
Valneva at a glance
Commercial vaccines
€m
Total revenues in 2022
Unique vaccine development programs
Integrated
differentiated clinical and pre-clinical assets
robust commercial portfolio
Focused
on prevention of infectious diseases with significant unmet medical need
>700
employees in six countries